GHRP-6 Reconstitution Calculator

GHRP-6 is a synthetic hexapeptide and the original growth hormone–releasing peptide, first made in the 1980s. It binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, prompting your own pituitary to release pulses of growth hormone — it is not a steroid and contains no hormone itself. Among the common GHRPs it's the least selective and the one most defined by a single trait: it makes you intensely hungry. It's a research compound, not an approved medicine.

GHRP-6 is dosed in micrograms — a commonly cited "saturation" dose is about 100 mcg (roughly 1 mcg per kg of body weight), given subcutaneously two to three times a day on an empty stomach. Going much above that doesn't raise GH proportionally; it mainly pushes cortisol and prolactin higher. Its half-life is short, so doses are spread through the day. These are research-reference figures, not an approved schedule, and whether it suits you at all is a clinical question.

Add bacteriostatic water down the side of the dry vial and swirl gently — don't shake. For example, a 5 mg vial + 2.5 mL of water gives 2 mg/mL (2,000 mcg/mL); a 100 mcg dose is then 0.05 mL, which is 5 units on a U-100 insulin syringe. Match the calculator above to your actual vial size (5 mg and 10 mg are common) and target dose. Because doses are tiny micrograms, draw carefully — a single mis-measured unit is a meaningful percentage of the dose.

Yes — intense hunger is GHRP-6's defining feature, typically hitting 15–30 minutes after an injection. It's the strongest appetite stimulant of any GH peptide because it closely mimics ghrelin's signaling in the brain's hunger centers, and it isn't caused by low blood sugar. That makes GHRP-6 a poor fit for fat-loss goals and the reason researchers instead study it for the opposite problem — cachexia, wasting, or appetite loss. If minimal hunger is what you want, ipamorelin is the cleaner end of this family.

There's no human evidence that GHRP-6 causes cancer; the real, documented caution is the one shared by anything that raises GH/IGF-1 — that higher IGF-1 could theoretically feed an existing tumor, which is why GH-raising compounds are avoided in people with active cancer, not evidence that GHRP-6 starts cancer. Commonly reported effects are the strong hunger, mild water retention, and transient flushing or tingling; cortisol and prolactin can rise at higher doses. GHRP-6 is not FDA-approved for any use and is banned by WADA in sport. Store the dry vial cold and out of light; once reconstituted, keep it refrigerated and use within a few weeks.